IceCure Medical Ltd ICCM
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -96.28%
- 1 year
- -96.73%
- Market cap
- 3.16M
- Revenue (ttm)
- 3.34M
- EPS (ttm)
- -6.84
- Shares out
- 55.50M
- Forward P/E
- -4.48
- YTD return
- -96.28%
- 1-year return
- -96.73%
- Volume
- 42.21K
- Avg volume
- 144.51K
- Open
- 0.70
- Previous close
- 0.6899
- Day's range
- 0.68 – 0.73
- 52-week range
- 0.6807 – 21.90
- Beta
- 2.63
- Price target
- 3.37 (+394.6%)
- Earnings date
- Aug 20, 2024
ALL -330.8193 (-99.79%)
Key statistics
- Enterprise value
- 28.55M
- PEG ratio
- 0.00
- Price / sales
- 18.63
- Price / book
- 4.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.90%
- Free cash flow
- -6.62M
- Total cash
- 10.46M
- Total debt
- 520.00K
- Return on equity
- -94.22%
- Short % of float
- 0.98%
- 50-day average
- 0.74766
- 200-day average
- 0.852735
Analyst view
- Target (low)
- 2.50
- Target (mean)
- 3.37
- Target (high)
- 4.60
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate -0.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | -0.06 | +0.01 | +14.29% |
| May 28, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IceCure Medical Ltd
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- icecure-medical.com
News
IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting - IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer
Full Transcript: Icecure Medical Q2 2026 Earnings Call - IceCure Medical Receives Approval From China's National Medical Products Administration For Its ProSense System, Associated Cryoprobes
IceCure Medical Inks Distribution Agreement With Scovas Medical To Distribute IceCure's ProSense Cryoablation Systems In Netherlands - IceCure Medical Says JHM-IRB Of West Cancer Center & Research Institute In Germantown, Tennessee, Approves Post-Marketing Study For ProSense Cryoablation In Local Treatment Of Low-Risk Breast Cancer
- IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes
- Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate
Your note
Sign in to keep a note on ICCM — it syncs with the Stock Master app.